It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting

Özdemir, Nuriye; Abalı, Hüseyin; Öksüzoğlu, Berna; Budakoğlu, Burçin; Akmangit, İlkay; Zengi̇n, Nurullah

doi:10.1007/s00520-008-0498-x

Cited by 21 publications

(26 citation statements)

References 17 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, we did not find any significant difference between these venous entry methods. In addition, port inversion or flip-over is a very rare complication (19)(20)(21)(22)(23). It was very rare in our study as well.…”

Section: Discussionsupporting

confidence: 50%

Factors on Patency Periods of Subcutaneous Central Venous Port: Long-Term Results of 1,408 Patients

Arıbaş¹,

Tiken²,

Aribas

et al. 2016

Iran J Radiol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 50%

Factors on Patency Periods of Subcutaneous Central Venous Port: Long-Term Results of 1,408 Patients

Arıbaş¹,

Tiken²,

Aribas

et al. 2016

Iran J Radiol

View full text Add to dashboard Cite

show abstract

“…Included studies were carried out in 14 different geographical regions and countries: the USA (n=14) [7, 8, 11, 16, 19, 21-23, 38, 42, 48, 49, 51, 55], Germany (n=6) [33-35, 43, 57, 60], Italy (n=4) [3][4][5]20], Spain (n=4) [12,17,46,47], the Netherlands (n=4) [26,32,45,59], France (n=4) [15,31,36,37], Belgium (n=3) [10,24,44], Taiwan (n=3) [13,14,29], Turkey (n=3) [18,41,50], Europe (n=2) [6,28], Switzerland (n=2) [25,58], Brazil (n=2) [40,61], Japan (n=2) [1,54], Austria (n=1) [27], Canada (n=1) [9], Portugal (n=1) [2], and Sweden (n=1) [30]. Of the 57 publications, five involved multicenter studies [6,28,30,36,37].…”

Section: Characteristics Of Selected Articlesmentioning

confidence: 99%

Systematic review: malfunction of totally implantable venous access devices in cancer patients

Goossens

Stas

Jérôme

et al. 2011

Support Care Cancer

View full text Add to dashboard Cite

Heterogeneity in the definitions used to describe device malfunction was evident. A broad range in the reported incidence of malfunction and in the kind of calculation and reporting methods was also found. Methodological quality of the studies was often poor. Standardization of definitions and accurate outcome measurement is needed. Calculation and report of malfunction incidence should be based on prospective data collected at the moment of an accession attempt.

show abstract

“…19,35,61 Although ratio of the catheter-associated venous thrombosis was reported up to 66 %, few were noted to be symptomatic (3 to 32%). 1,19,41,44,[62][63][64][65] If the patient is asymptomatic and the catheter is functioning, further progression of venous thrombosis may be prevented with anticoagulant therapy without the need of TIVAD removal. 1,19,35,61 Biffi et al demonstrated that catheterrelated thrombosis was highest on entries through IJV (17.1%).…”

Section: Late Postprocedural Complicationsmentioning

confidence: 99%

A Comparative Study of Low-Profile and Regular Type Totally Implantable Venous Access Devices in Patients with Malignant Tumors: Retrospective Analysis of 4501 Implantations.

Akmangit¹

2014

UHOD

View full text Add to dashboard Cite

The purpose of this study was to evaluate safety and efficacy of image-guided radiological totally implantable venous access devices with special reference to rate of skin complications of both regular and low-profile types. 4395 patients were referred to Interventional Radiology Unit between March 2003-September 2013. 4501 implantations of totally implantable venous access device were performed in patients under sonography and fluoroscopy. During this period 2299 regular-type and 2202 low-profile type totally implantable venous access devices were used. Success rate, periprocedural early and long-term complications were evaluated. Periprocedural and early complications of totally implantable venous access devices included 16 (0.4%) arterial punctures, 101 (2.2%) minor hematoma, 1 (%0.02) disconnection of the catheter, 4 (0.09%) septum separation, 38(0.8%) minor erythema-pain and tenderness, 23 (0.5%) short term fever without bacteriemia and 25 (0.6%) inversion of the port. Late complications included 6(0.1%) cellulitis, 8 (0.2%) bacteriemia and sepsis, 305 (6.8%) venous thrombosis, 62 (1.4%) catheter thrombosis, 6 (0.1%) catheter migration and 3 (0.07%) catheter fracture. A total of 53 (1.18%) skin perforation were seen. There was statistically significant difference between regular and low-profile totally implantable venous access devices particularly in patients with normal and thinner subcutaneous fat tissue (p= 0.024 and <0.001 respectively). The present study is the largest series in the literature in patients with malignant tumors. Image-guided radiological totally implantable venous access device placement is safe and reliable method with a low risk of complications and the results of this study further justify the use of low profile totally implantable venous access device based on lower skin complications. Keywords: Port, TIVAD, Low-profile, Regular, Skin perforation ÖZET Malign Tümörlü Olgularda Düşük Profilli ve Standard Tip TİVEC kullanımının Karşılaştırmalı Çalışması: 4501 Olgunun Retrospektif AnaliziBu çalışmanın amacı radyolojik görüntüleme eşliğinde yerleştirilen, standart ve düşük profilli, tamamen implante edilebilir venöz erişim cihazlarının cilt komplikasyonları yönünden güvenirlik ve etkinliğinin değerlendirilmesiydi. Mart 2003 ve Eylül 2013 tarihleri arasında 4395 hasta Girişimsel Radyoloji ünitesine başvurdu. Bu hastalara ultrasonografi ve floroskopi eşliğinde 4501 tamamen implante edilebilir venöz erişim cihazı yerleştirildi. Bu süre içinde 2299 standard tipte, 2202 düşük profilli tamamen implante edilebilir venöz erişim cihazı kullanıldı. Başarı oranı, işlem sırasında, erken ve geç komplikasyonlar değerlendirildi. Tamamen implante edilebilir venöz erişim cihazı yerleştirilmesi sırasında gelişen erken dönem komplikasyonlar arteriel giriş 16 (%0.4), minör hematom 101 (%2.2), kateter ayrılması 1 (%0.02), septum ayrılması 4 (%0.09), minör eritem-ağrı ve hassasiyet 38 (%0.8), bakteriyemi olmaksızın kısa süren ateş 23 (%0.5) ve portun ters dönmesi 25 (%0.6) olarak sıralandı. Geç kompl...

show abstract

It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting

Abstract: Chemotherapy administration immediately after VPC implantation appears safe without increased acute and chronic complications in inpatient setting.

Cited by 21 publications

References 17 publications

Factors on Patency Periods of Subcutaneous Central Venous Port: Long-Term Results of 1,408 Patients

Factors on Patency Periods of Subcutaneous Central Venous Port: Long-Term Results of 1,408 Patients

Systematic review: malfunction of totally implantable venous access devices in cancer patients

A Comparative Study of Low-Profile and Regular Type Totally Implantable Venous Access Devices in Patients with Malignant Tumors: Retrospective Analysis of 4501 Implantations.

Contact Info

Product

Resources

About